The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kamilova D.P.

«Mother and Child» Clinic, Moscow, Russia

Iakunina N.A.

Nauchnyĭ tsentr akusherstva, ginekologii i perinatologii im. akad. V.I. Kulakova, Moskva

Ketyladze T.M.

«Mother and Child» Clinic, Moscow, Russia

Luteal phase support as one of key factors of success in assisted reproduction

Authors:

Kamilova D.P., Iakunina N.A., Ketyladze T.M.

More about the authors

Journal: Russian Journal of Human Reproduction. 2019;25(4): 51‑60

DOI: 10.17116/repro20192504151

Views: 3528

Downloaded: 97

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Kamilova DP, Iakunina NA, Ketyladze TM. Luteal phase support as one of key factors of success in assisted reproduction. Russian Journal of Human Reproduction. 2019;25(4):51‑60. (In Russ.)
https://doi.org/10.17116/repro20192504151

 
МСФ на ЯМ
Close metadata
Recommended articles:
The role of inte­rgenic inte­ractions in the formation of peri­natal complications of gestational diabetes mellitus in pregnant women after assi­sted reproductive technologies. Russian Journal of Human Reproduction. 2024;(2):51-61
Analysis of the effe­ctiveness of various methods of mana­ging patients with endo­metriosis and justification for long-term personalized anti-relapse therapy with dydrogesterone as part of their combination treatment stra­tegy. Russian Journal of Human Reproduction. 2024;(2):102-111
Assi­sted reproductive technologies and the risk of placenta accreta. Russian Journal of Human Reproduction. 2024;(3):43-49
IVF outcomes with various degrees of pathozoospermia. Russian Journal of Human Reproduction. 2024;(3):115-120
Calcium-phosphorus meta­bolism and assi­sted reproductive technologies: inte­rsection points. Russian Journal of Human Reproduction. 2024;(4):19-28
The dile­mma of mana­gement of patients with endo­metrioma and infe­rtility. Russian Journal of Human Reproduction. 2024;(4):29-37
The place of GnRH anta­gonists in modern ART programs: the possibilities of using of new drug of gani­relix. Russian Journal of Human Reproduction. 2024;(4):38-50
An inte­grated approach to endo­metrial examination in case of repeated failures in ART cycles: a pilot study. Russian Journal of Human Reproduction. 2024;(4):51-58
Arti­ficial inte­lligent systems in the deve­lopment of assi­sted reproductive technologies. Russian Bulletin of Obstetrician-Gynecologist. 2024;(2):19-29
Correlation depe­ndence of tissue inhi­bitor of meta­lloproteinase-1 levels and follicular fluid morphology in patients with combined (uterine myoma and endo­metriosis) infe­rtility in the ART-programs. Russian Bulletin of Obstetrician-Gynecologist. 2024;(4):21-28

Infertility is one of the most pressing problems of modern medicine. To overcome the inability to have children all over the world for more than 40 years, assisted reproductive technologies (ART) are used and continuously improved, their acceptability, accessibility and effectiveness are increased. One of the key factors in the success of infertility treatment is the support of the luteal phase with ART. We have analyzed the use of various progesterone drugs in the maintenance therapy regimen, the purpose of which was to study the frequency of pregnancy in IVF cycles depending on the drugs used. The study group consisted of 365 patients of young reproductive age, who in each of the analyzed groups after the transfer of embryos were prescribed dydrogesterone, micronized vaginal progesterone (MVP) in capsules or in the form of a gel.

Keywords:

assisted reproductive technologies
ART
IVF
luteal phase
progestogenes
progesterone
dydrogesterone

Authors:

Kamilova D.P.

«Mother and Child» Clinic, Moscow, Russia

Iakunina N.A.

Nauchnyĭ tsentr akusherstva, ginekologii i perinatologii im. akad. V.I. Kulakova, Moskva

Ketyladze T.M.

«Mother and Child» Clinic, Moscow, Russia

List of references:

  1. Vspomogatel’nye reproduktivnye tekhnologii i iskusstvennaya inseminaciya. Klinicheskie rekomendacii (protokol lecheniya). Moscow. 2019. Accessed July 28, 2019. (In Russ.). Available at:]https://base.garant.ru/72245638/
  2. Zhenskoe besplodie. Klinicheskie rekomendatsii. M. 2019. Accessed July 28, 2019. (In Russ.) Available at: http://pravo-med.ru/legislation/fz/14786/
  3. Besplodnyj brak: versii i kontraversii. Pod red. Radzinskogo VE. M.: GEOTAR-Media. 2018. (In Russ.)
  4. WHO. Mother or nothing: the agony of infertility. Buletin of the World Health Organization. 2010;88(12):877-953.
  5. Tabletka na schast’e. Primenenie sovremennyh lekarstv pozvolit dopolnitel’no povysit’ rozhdaemost’. Rossijskaya Gazeta: Specvypusk — Zdravoohranenie. 4 marta 2019 g. No 7805:A2. (In Russ.)
  6. Ginekologiya: Nacional’noe rukovodstvo. Pod red. Savel’evoy GM, Sukhikh GT, Serova VN, Manukhina IB, Radzinskogo VE. 2-e izdanie, pererabotannoe i dopolnennoe. M.: GEOTAR-Media, 2017. (In Russ.)
  7. Nifantova RV. Vspomogatel’nye reproduktivnye tekhnologii v terapii zhenskogo i muzhskogo besplodiya. Problemy i perspektivy. Social’no-ekonomicheskie problemy vosproizvodstva i zameshcheniya pokolenii naseleniya Rossii v XXI v. Materialy nauchno-prakticheskoy konferentsii. Ekaterinburg: IE UrO RAN, 2011;132-135. (In Russ.)
  8. Serov V. Test ne projden. Vozmozhnost’ imet’ zdorovyh detej vo mnogom zavisit ot pravil’nogo polovogo povedeniya. Rossijskaya Gazeta: Specvypusk — Zdravoohranenie. 4 marta 2019 g. No 7805. S.A2. (In Russ.)
  9. Prokhorenko NF. Demographic potential: additional aspects. ORGZDRAV: novosti, mneniya, obuchenie. Vestnik VSHOUZ. 2019;5(2). (In Russ.) https://doi.org/10.24411/2411-8621-2019-12002
  10. Novostnoe soobshchenie. V Ivanove obsudili, kak sdelat’ rabotu sluzhb rodovspomozheniya bolee effektivnoy. Accessed July 28, 2019. (In Russ.). Available at: https://ivteleradio.ru/video/2019/06/07/v_ivanove_obsudili_kak_sdelat_rabotu_sluzhb_rodovspomozheniya_bolee_effektivnoy
  11. Jones GS, Garcia J, Acosta A. Luteal phase evaluation in in-vitro fertilization. In: Edwards RG, Purdy JM. Human Conception In Vitro. London, UK: Academic Press; 1982;297-310.
  12. Rosenberg SM, Luciano AA, Riddick DH. The luteal phase defect: the relative frequency of, and encouraging response to, treatment with vaginal progesterone. Fertility and Sterility.1980;34(1):17-20.
  13. Edwards RG, Steptoe PC, Purdy JM. Establishing full-term human pregnancies using cleaving embryos grown in vitro. British Journal of Obstetrics and Gynecology. 1980;87(9):737-756.
  14. Kerin JF, Broom TJ, Ralph MM, Edmonds DK, Warnes GM, Jeffrey R, Crocker JM, Godfrey B, Cox LW, Seamark RF, Matthews CD. Human luteal phase function following oocyte aspiration from the immediately preovular graafian follicle of spontaneous ovular cycles. British Journal of Obstetrics and Gynecology. 1981;88(10):1021-1028.
  15. Smitz J, Erard P, Camus M, Devroey P, Tournaye H, Wisanto A, Van Steirteghem AC. Pituitary gonadotrophin secretory capacity during the luteal phase in superovulation using GnRH-agonists and HMG in a desensitization or flare-up protocol. Human Reproduction. 1992;7(9):1225-1229.
  16. Practice Committee of Society for Assisted Reproductive Technology, Practice Committee of American Society for Reproductive Medicine. Fertility and Sterility. 2008;90:S163-S164.
  17. Fatemi HM. Assessment of the luteal phase in stimulated and substituted cycles. Facts Views and Vision in Obgyn. 2009;1(1):30-46.
  18. Miyake A, Aono T, Kinugasa T, Tanizawa O, Kurachi K. Suppression of serum levels of luteinizing hormone by short- and long-loop negative feedback in ovariectomized women. The Journal of Endocrinology. 1979;80:353-356.
  19. Tavaniotou A, Devroey P. Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles. Reproductive BioMedicine Online. 2006;13(3):326-330.
  20. Albano C, Smitz J, Camus M, Riethmüller-Winzen H, Weigel M, Diedrich K, Van Steirteghem AC, Devroey P. Hormonal profile during the follicular phase in cycles stimulated with a combination of human menopausal gonadotrophin and gonadotrophin-releasing hormone antagonist (Cetrorelix). Human Reproduction.1996;11(10):2114-2118.
  21. Elter K, Nelson LR. Use of third generation gonadotropin-releasing hormone antagonists in in vitro fertilization-embryo transfer: a review. Obstetrical and Gynecological Survey. 2001;56(9):576-588.
  22. Ragni G, Vegetti W, Baroni E, Colombo M, Arnoldi M, Lombroso G, Crosignani PG. Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist. Human Reproduction. 2001;16(11):2258-2262.
  23. Albano C, Grimbizis G, Smitz J, Winzen H, Reissmann T, Van Steirteghem A, Devroey P. The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix. Fertility and Sterility. 1998;70:357-359.
  24. Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, Bustion S, Loumaye E, Fauser BC. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. The Journal of Clinical Endocrinology and Metabolism. 2003;88(9):4186-4192.
  25. Dal Prato L, Borini A. Use of antagonists in ovarian stimulation protocols. Reproductive BioMedicine Online. 2005;10(3):330-338.
  26. Yanushpolsky E. Evidence-based use of progesterone in IVF. In: Racowsky C, Carrell DT, Schlegel PN, Fauser BC, eds. Biennial Review of Infertility (Volume 2). New York, NY: Springer, 2011;79-90.
  27. Tarlatzis BC, Kolibianakis EM. GnRH agonists vs antagonists. Best Practice and Research. Clinical Obstetrics and Gynaecology. 2007;21(1):57-65.
  28. Fauser BC, Devroey P. Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends in Endocrinology and Metabolism: TEM. 2003;14(5):236-242.
  29. Lawrenz B, Coughlan C, Fatemi HM. Individualized luteal phase support. Current Opinion in Obstetrics and Gynecology. 2019;31(3):177-182. https://doi.org/10.1097/GCO.0000000000000530
  30. Csapo AI, Pulkkinen MO, Ruttner B, Sauvage JP, Wiest WG. The significance of the human corpus luteum in pregnancy maintenance. I. Preliminary studies. American Journal of Obstetrics and Gynecology. 1972;112(8):1061-1067.
  31. Csapo AI, Pulkkinen MO, Wiest WG. Effects of luteectomy and progesterone replacement therapy in early pregnant patients. American Journal of Obstetrics and Gynecology. 1973;115(6):759-765.
  32. Kolibianakis EM, Devroey P. The luteal phase after ovarian stimulation. Reproductive BioMedicine Online. 2002;5(Suppl 1):26-35.
  33. Filicori M, Butler JP, Crowley Jr WF. Neuroendocrine regulation of the corpus luteum in the human. Evidence for pulsatile progesterone secretion. Journal of Clinical Investigation. 1984;73(6):1638-1647.
  34. Hubayter ZR, Muasher SJ. Luteal supplementation in in vitro fertilization: more questions than answers. Fertility and Sterility. 2008;89(4):749-758.
  35. Van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. The Cochrane Database of Systematic Reviews. 2011;10:CD009154.
  36. Martin J, Dominguez F, Avila S. Human endometrial receptivity: gene regulation. Journal of Reproductive Immunology. 2002;55:131-139.
  37. Bulletti C, de Ziegler D. Uterine contractility and embryo implantation. Current Opinion in Obstetrics and Gynecology. 2005;17(3):265-276.
  38. Fanchin R, Righini C, de Ziegler D, Olivennes F, Ledée N, Frydman R. Effects of vaginal progesterone administration on uterine contractility at the time of embryo transfer. Fertility and Sterility. 2001;75(6):1136-1140.
  39. Van der Linden M, Buckingham K, Farquhar C, Kremer JAM, Metwally M. Luteal phase support for assisted reproduction cycles. The Cochrane Database of Systematic Reviews. 2015;7:CD009154. https://doi.org/10.1002/14651858.CD009154
  40. Practice Committee of the American Society for Reproductive Medicine. Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin. Fertility and Sterility. 2008;89(4):789-792. https://doi.org/10.1016/j.fertnstert.2008.02.012
  41. Van Steirteghem AC, Smitz J, Camus M, Van Waesberghe L, Deschacht J, Khan I, Staessen C, Wisanto A, Bourgain C, Devroey P. The luteal phase after in-vitro fertilization and related procedures. Human Reproduction. 1988;3(2):161-164.
  42. Smitz J, Devroey P, Camus M, Deschacht J, Khan I, Staessen C, Van Waesberghe L, Wisanto A, Van Steirteghem AC. The luteal phase and early pregnancy after combined GnRH-agonist/HMG treatment for superovulation in IVF or GIFT. Human Reproduction. 1988;3(5):585-590.
  43. Devroey P, Palermo G, Bourgain C, Van Waesberghe L, Smitz J, Van Steirteghem AC. Progesterone administration in patients with absent ovaries. International Journal of Fertility. 1989;34(3):188-193.
  44. Smitz J, Devroey P, Faguer B, Bourgain C, Camus M, Van Steirteghem AC. A prospective randomized comparison of intramuscular or intravaginal natural progesterone as a luteal phase and early pregnancy supplement. Human Reproduction. 1992;7(2):168-175.
  45. Pritts EA, Atwood AK. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Human Reproduction. 2002;17(9):2287-2299.
  46. Simon JA, Robinson DE, Andrews MC, Hildebrand JR III, Rocci ML, Jr, Blake RE, Hodgen GD. The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone. Fertility and Sterility. 1993;60(1):26-33.
  47. Tavaniotou A, Smitz J, Bourgain C, Devroey P. Comparison between different routes of progesterone administration as luteal phase support in infertility treatments. Human Reproduction Update. 2000;6(2):139-148.
  48. Vaisbuch E, Leong M, Shoham Z. Progesterone support in IVF: is evidence- based medicine translated to clinical practice? A worldwide web-based survey. Reproductive BioMedicine Online. 2012;25(2):139-145. https://doi.org/10.1016/j.rbmo.2012.04.005
  49. Sator M, Radicioni M, Cometti B, Loprete L, Leuratti C, Schmidl D, Garhofer G. Pharmacokinetics and safety profile of a novel progesterone aqueous formulation administered by the s.c. route. Gynecological Endocrinology. 2013;29(3):205-208. https://doi.org/10.3109/09513590.2012.736560
  50. Besins Healthcare (UK) Ltd. Utrogestan 100 mg capsules Summary of Product Characteristics. Accessed July 28, 2019. Available at: https://www.medicines.org.uk/emc/product/352/smpc
  51. Beltsos AN, Sanchez MD, Doody KJ, Bush MR, Domar AD, Collins MG. Patients’ administration preferences: progesterone vaginal insert (Endometrin) compared to intramuscular progesterone for luteal phase support. Reproductive Health. 2014;11:78. https://doi.org/10.1186/1742-4755-11-78
  52. Bouckaert Y, Robert F, Englert Y, De Backer D, De Vuyst P, Delbaere A. Acute eosinophilic pneumonia associated with intramuscular administration of progesterone as luteal phase support after IVF: case report. Human Reproduction. 2004;19(8):1806-1810.
  53. Veysman B, Vlahos I, Oshva L. Pneumonitis and eosinophilia after in vitro fertilization treatment. Annals of Emergency Medicine. 2006;47(5):472-475.
  54. Phy JL, Weiss WT, Weiler CR, Damario MA. Hypersensitivity to progesterone-in-oil after in vitro fertilization and embryo transfer. Fertility and Sterility. 2003;80(5):1272-1275.
  55. Vaisbuch E, de Ziegler D, Leong M, Weissman A, Shoham Z. Luteal-phase support in assisted reproduction treatment: real-life practices reported worldwide by an updated website-based survey. Reproductive BioMedicine Online. 2014;28(3):330-335. https://doi.org/10.1016/j.rbmo.2013.10.022
  56. Merriam KS, Leake KA, Elliot M, Matthews ML, Usadi RS, Hurst BS. Sexual Absorption of Vaginal Progesterone: A Randomized Control Trial. International Journal of Endocrinology. 2015; 2015:Article ID 685281. https://doi.org/10.1155/2015/685281
  57. Tournaye H, Sukhikh GT, Kahler E, Griesinger G. A phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization. Human Reproduction. 2017;32(5):1019-1027. https://doi.org/10.1093/humrep/dex023
  58. Griesinger G, Tournaye H, Macklon N, Petraglia F, Arck P, Blockeel C, van Amsterdam P, Pexman-Fieth C, Fauser BC. Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction. Reproductive BioMedicine Online. 2019;38(2):249-259. https://doi.org/10.1016/j.rbmo.2018.11.017
  59. Mirza FG, Patki A, Pexman-Fieth C. Dydrogesterone use in early pregnancy. Gynecological Endocrinology. 2016;32(2):97-106. https://doi.org/10.3109/09513590.2015.1121982
  60. Rižner TL, Brožič P, Doucette C, Turek-Etienne T, Muller-Vieira U, Sonneveld E, van der Burg B, Bocker C, Husen B. Selectivity and potency of the retroprogesterone dydrogesterone in vitro. Steroids. 2011;76(6):607-615. https://doi.org/10.1016/j.steroids.2011.02.043
  61. Lockwood G, Griesinger G, Cometti B, 13 European Centers. Subcutaneous progesterone versus vaginal progesterone gel for luteal phase support in in vitro fertilization: a noninferiority randomized controlled study. Fertility and Sterility. 2014;101(1):112-119.e113. https://doi.org/10.1016/j.fertnstert.2013.09.010
  62. Tomic V, Tomic J, Klaic DZ, Kasum M, Kuna K. Oral dydrogesterone versus vaginal progesterone gel in the luteal phase support: randomized controlled trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2015;186:49-53. https://doi.org/10.1016/j.ejogrb.2014.11.002
  63. Barbosa MW, Silva LR, Navarro PA, Ferriani RA, Nastri CO, Martins WP. Dydrogesterone vs progesterone for luteal-phase support: systematic review and meta-analysis of randomized controlled trials. Ultrasound in Obstetrics and Gynecology. 2016;48(2):161-170. https://doi.org/10.1002/uog.15814
  64. Chakravarty BN, Shirazee HH, Dam P, Goswami SK, Chatterjee R, Ghosh S. Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. Journal of Steroid Biochemistry and Molecular Biology. 2005;97:416-420.
  65. Griesinger G, Blockeel C, Sukhikh GT, Patki A, Dhorepatil B, Yang DZ, Chen ZJ, Kahler E, Pexman-Fieth C, Tournaye H. Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in in vitro fertilization: a randomized clinical trial. Human Reproduction. 2018;33(12):2212-2221. https://doi.org/10.1093/humrep/dey306
  66. Instrukciya po medicinskomu primeneniyu lekarstvennogo preparata Dyufaston on 26.02.2018. Accessed July 28, 2019 (In Russ.). Available at: https://medi.ru/instrukciya/dyufaston_2881/
  67. ASRM 2018. Scientific Abstracts of the 74th Scientific Congress of the American Society for Reproductive Medicine, October 6-10, 2018; Denver, Colorado; 2018: e90.
  68. ESHRE 2019. Oral presentation of G. Griesinger. June 25, 2019; Vienna, Austria. Accessed July 28, 2019. Available at: https://www.eshre.eu/ESHRE2019
  69. Kumar A, Begum N, Prasad S, Aggarwal S, Sharma S. Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo-controlled trial. Fertility and Sterility. 2014;102(5):1357.e3-63.e3. https://doi.org/10.1016/j.fertnstert.2014.07.1251
  70. Pandian RU. Dydrogesterone in threatened miscarriage: a Malaysian experience. Maturitas. 2009;65(Suppl 1):S47-S50.
  71. Lee HJ, Park TC, Kim HJ, Norwitz E, Lee B.The Influence of Oral Dydrogesterone and Vaginal Progesterone on Threatened Abortion: A Systematic Review and Metaanalysis. BioMed Research International. 2017;2017:3616875. https://doi.org/10.1155/2017/3616875
  72. Saccone G, Schoen C, Franasiak JM, Scott RT Jr, Berghella V. Supplementation with progestogens in the first trimester of pregnancy to prevent miscarriage in women with unexplained recurrent miscarriage: a systematic review and metaanalysis of randomized, controlled trials. Fertility and Sterility. 2017;107(2):430-438. https://doi.org/10.1016/j.fertnstert.2016
  73. Coomarasamy A, Williams H, Truchanowicz E, Seed PT, Small R, Quenby S, Gupta P, Dawood F, Koot YE, Bender Atik R, Bloemenkamp KW, Brady R, Briley AL, Cavallaro R, Cheong YC, Chu JJ, Eapen A, Ewies A, Hoek A, Kaaijk EM, Koks CA, Li TC, MacLean M, Mol BW, Moore J, Ross JA, Sharpe L, Stewart J, Vaithilingam N, Farquharson RG, Kilby MD, Khalaf Y, Goddijn M, Regan L, Rai R. A Randomized Trial of Progesterone in Women with Recurrent Miscarriages. New England Journal of Medicine. 2015;373(22):2141-2148. https://doi.org/10.1056/NEJMoa1504927
  74. Coomarasamy A, Devall AJ, Cheed V, Harb H, Middleton LJ, Gallos ID, Williams H, Eapen AK, Roberts T, Ogwulu CC, Goranitis I, Daniels JP, Ahmed A, Bender-Atik R, Bhatia K, Bottomley C, Brewin J, Choudhary M, Crosfill F, Deb S, Duncan WC, Ewer A, Hinshaw K, Holland T, Izzat F, Johns J, Kriedt K, Lumsden MA, Manda P, Norman JE, Nunes N, Overton CE, Quenby S, Rao S, Ross J, Shahid A, Underwood M, Vaithilingam N, Watkins L, Wykes C, Horne A, Jurkovic D. A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy. New England Journal of Medicine. 2019;380(19):1815-1824. https://doi.org/10.1056/NEJMoa1813730
  75. Recurrent pregnancy loss. Guideline of the European Society of Human Reproduction and Embryology (ESHRE). 2017. Accessed July 28, 2019. Available at: https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Recurrent-pregnancy-loss
  76. Toth B, Würfel W, Bohlmann M, Zschocke J, Rudnik-Schöneborn S, Nawroth F, Schleußner E, Rogenhofer N, Wischmann T, von Wolff M, Hancke K, von Otte S, Kuon R, Feil K, Tempfer C. Recurrent Miscarriage: Diagnostic and Therapeutic Procedures. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry Number 015/050). Geburtshilfe und Frauenheilkunde. 2018;78(4):364-381. https://doi.org/10.1055/a-0586-4568
  77. Schindler AE, Carp H, Druckmann R, Genazzani AR, Huber J, Pasqualini J, Schweppe KW, Szekeres-Bartho J. European Progestin Club Guidelines for prevention and treatment of threatened or recurrent (habitual) miscarriage with progestogens. Gynecological Endocrinology. 2015;31(6):447-449. https://doi.org/10.3109/09513590.2015.1017459
  78. Vykidysh v rannie sroki beremennosti: diagnostika i taktika vedeniya. Klinicheskie rekomendacii (Protokol lecheniya). Pis’mo Ministerstva zdravoohraneniya Rossijskoj Federacii ot №15-4/10/2-3482 on 07 iyunya 2016 g. Accessed July 28, 2019. (In Russ.) Available at: https://rulaws.ru/acts/Pismo-Minzdrava-Rossii-on 07.06.2016-N-15-4_10_2-3482
  79. Tetruashvili NK, Agadganova AA. Didrogesterone in the treatment of threatening and habitual miscarriage. Medicinskiy sovet. 2018;13:34-38. (In Russ.)
  80. Patki A, Pawar VC. Modulating fertility outcome in assisted reproductive technologies by the use of dydrogesterone. Gynecological Endocrinology. 2007;23(Suppl 1):68-72.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.